HBsAg–TBK1 Interaction Drives Early Autophagy and IFN Suppression in HBV

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection affects over 350 million people globally and is a major predisposing factor for liver cancer (paper). HBV encodes several structural and regulatory proteins, with hepatitis B surface antigen (HBsAg) being critical for viral assembly, secretion, and host cell entry. Despite advances in understanding HBV pathogenesis, the interplay between host innate immunity and autophagy in infected cells remains incompletely defined. Innate immunity relies on pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), to trigger antiviral interferon (IFN) responses, while autophagy, a process for degrading cytoplasmic components, can be co-opted by viruses to evade immune surveillance. This study addresses a central question: how does HBsAg modulate host signaling pathways to suppress interferon production and promote autophagy, thereby facilitating persistent infection?

Key Innovation from the Reference Study

The core innovation of Luo et al. (2025) is the demonstration that HBsAg directly interacts with TANK-binding kinase 1 (TBK1), a pivotal signaling hub for both type I IFN induction and autophagy regulation (paper). The authors reveal a dual effect: HBsAg augments TBK1 dimerization and phosphorylation, which paradoxically leads to selective activation of autophagy (via p62 phosphorylation) while disrupting the TBK1–IRF3 complex necessary for IFN-β induction. This mechanistic bifurcation explains how HBV can simultaneously inhibit antiviral responses and trigger early autophagic processes that may support viral replication and persistence.

Methods and Experimental Design Insights

The authors combined ex vivo, in vivo, and molecular biology approaches to dissect the HBsAg–TBK1 axis:

• Cellular Models: Human hepatocyte-derived cell lines expressing HBsAg were employed to study intracellular signaling and autophagy dynamics.
• Mouse Models: Transgenic mice expressing HBsAg and liver tissue from chronic HBV patients were analyzed to confirm in vivo relevance.
• Biochemical Assays: Co-immunoprecipitation and mutagenesis mapped the interaction domains between HBsAg and TBK1.
• Autophagy Assays: Accumulation of autophagosomes was tracked by LC3-II conversion and p62 phosphorylation. Inhibition of autophagic flux was confirmed by monitoring autophagosome–lysosome fusion (SNAP29 promoter activity).
• Pharmacological Modulation: The selective TBK1 inhibitor BX795 was used to dissect the dependency of observed effects on TBK1 activity.
• Readouts for IFN Signaling: Phosphorylation status of IRF3 and downstream IFN-stimulated gene (ISG) expression were measured following stimuli.

Protocol Parameters

• autophagy assay | LC3-II, p62 phosphorylation | hepatocyte models, in vivo liver tissue | Validates autophagosome accumulation and incomplete autophagy upon HBsAg expression | paper
• SNAP29 promoter analysis | luciferase reporter, mRNA quant | hepatocyte lines | Dissects autophagosome–lysosome fusion block induced by HBsAg | paper
• TBK1 inhibition | BX795, 2–5 μM | in vitro cell models | Demonstrates dependency of autophagy induction on TBK1 activation | paper
• IFN pathway analysis | IRF3 phosphorylation, ISG15/ISG56 expression | ex vivo and in vivo | Confirms suppression of IFN responses by HBsAg–TBK1 interaction | paper
• Recommended chloroquine diphosphate use | 15–40 μM (in vitro); 25–50 mg/kg (mouse models) | cancer/autophagy workflows | Benchmarked for autophagy modulation and assay control | product_spec

Core Findings and Why They Matter

The study's main findings are:

• HBsAg suppresses type I IFN signaling by disrupting TBK1–IRF3 interactions, thereby dampening the host antiviral response (paper).
• HBsAg drives early-stage autophagy via enhanced TBK1 dimerization and p62 phosphorylation, but autophagic flux is incomplete due to a block at the autophagosome–lysosome fusion step (mediated by SNAP29 inhibition).
• These effects are recapitulated in vivo: Both HBsAg-transgenic mice and liver tissue from chronic HBV patients show suppressed IFN-β signaling and accumulation of immature autophagosomes.

These results have two major implications. First, they clarify a mechanism by which HBV evades innate immunity, highlighting the importance of TBK1 as a viral target. Second, they illustrate that the manipulation of autophagy is nuanced: HBV induces autophagy up to a point that favors its own replication, but blocks completion to avoid degradation of viral components. This specific crosstalk suggests new strategies for intervening in chronic infection and supports the use of precise autophagy modulators in research.

Comparison with Existing Internal Articles

Several internal resources explore the utility of autophagy modulation in cancer and virology research:

• The article "Chloroquine Diphosphate: Mechanistic Pathways and Translational Research" discusses how Chloroquine diphosphate (4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid) serves as a TLR7/9 inhibitor and autophagy modulator, offering mechanistic insights for researchers seeking to navigate complex autophagy signaling landscapes. The reference study's focus on TBK1-mediated early autophagy connects directly to these workflows, where modulation of autophagic flux is a critical experimental lever (source: paper, workflow_recommendation).
• "Chloroquine Diphosphate in Cancer Research: Autophagy Assay Excellence" further elaborates on optimizing autophagy assays and therapy sensitization protocols. The incomplete autophagy described in the HBsAg–TBK1 study provides a valuable disease model for benchmarking such modulators and assessing their impact on both autophagic flux and immune signaling (source: paper, workflow_recommendation).

By bridging findings from HBV infection to cancer and immunology research, these internal articles underscore the translational relevance of precise autophagy modulators for dissecting host–pathogen interactions and therapeutic resistance.

Limitations and Transferability

While this study provides compelling mechanistic evidence, several limitations should be considered:

• Model specificity: The primary data derive from hepatocyte cell lines, HBsAg-transgenic mice, and patient liver samples. While highly relevant for HBV biology, direct extrapolation to other viral systems or tissue types requires caution (source: paper).
• Autophagy flux measurement: The study confirms incomplete autophagy by measuring autophagosome accumulation and SNAP29 promoter repression but does not exhaustively characterize all flux checkpoints or downstream consequences.
• Therapeutic translation: Although the mechanistic findings highlight TBK1 as a potential intervention target, the study does not address how pharmacological autophagy modulators (e.g., Chloroquine diphosphate) would impact the viral life cycle or immune response in the context of chronic HBV infection.

These factors delineate the boundaries of transferability, but the described mechanisms provide a robust framework for future research on autophagy–immunity crosstalk in both infectious and neoplastic diseases.

Why this cross-domain matters, maturity, and limitations

The intersection of autophagy regulation and innate immunity is increasingly recognized as a critical node in both viral pathogenesis and cancer therapy resistance. The HBsAg–TBK1 axis described here not only clarifies HBV's immune evasion strategies but also models how incomplete autophagy can influence cellular responses to stress—a principle widely applicable in oncology and immunology workflows (source: paper, workflow_recommendation). However, while the mechanistic bridge is strong, clinical translation for cancer or other viral infections will require additional, context-specific validation.

Research Support Resources

For researchers aiming to interrogate autophagy and immune signaling pathways in viral or cancer models, robust experimental controls and modulators are essential. Chloroquine diphosphate (SKU A8628), with established IC50 values of 15–40 μM in vitro and well-defined solubility properties, is widely used for autophagy assay modulation and therapy sensitization in cancer research (source: product_spec, workflow_recommendation). Its dual action as a TLR7 and TLR9 inhibitor and autophagy modulator makes it suitable for studies dissecting the balance between innate immunity and autophagic flux. For detailed protocol guidance and advanced use-cases in cancer or infectious disease research, consult internal resources such as Mechanistic Pathways and Autophagy Assay Excellence. APExBIO’s Chloroquine diphosphate is intended solely for research use and can support experimental workflows modeled on the mechanistic insights from this and related studies.